Table 7.
Treatment and outcome
| Combination therapy | |
|---|---|
| Multidrug Therapy | 44 (81.48%) |
| Most common multidrug (hydroxychloroquine and antivirals) | 31 (57.40%) |
| Therapeutics | |
|
Hydroxychloroquine (HCQ) Antivirals (Lopinavir/Ritonavir/Darunavir/Cobisitat) |
40 (74%) 30 (55.55%) |
| Azithromycin (AZT) | 10 (29.41%) |
| Remdesivir | 1 (1.85%) |
| Favipiravir (FAV) | 8 (14.81%) |
| Ceftriaxone (CEF) | 5 (9.25%) |
| Ganciclovir | 1 (1.85%) |
| Meropenem | 2 (3.7%) |
| Amoxicillin | 4 (7.47%) |
| Acyclovir | 7 (13%) |
| Arbidol | 1 (1.85%) |
| Ribavirin | 1 (1.85%) |
| Vancomycin | 4 (7.47%) |
| Plasmapheresis | 6 (11.11%) |
| Invasive ventilation | 14 (26%) |
| Non Invasive ventilation | 5 (9.25%) |
| IVIG | 6 (11.11%) |
| Steroids | 16 (30%) |
| Mannitol infusion | 1 (1.85%) |
| Outcome | |
| Recovery rate | 39 (72%) |
| Still in treatment | 6 (11.11%) |
| Mortality rate | 9 (17%) |